TP53 and ovarian cancer: Moreover, PANDAR exhibited higher expression in cisplatin-resistant ovarian cancer tissues and cells, compared with cisplatin-sensitive tissues and cells, and mechanistic studies showed that it negatively regulates cisplatin sensitivity in human ovarian cancer via PANDAR-SRFS2-p53 feedback regulation in the nucleus [48].